Search

Author/Creator Thomas, M.

1. 0047: Claudin-3 and Claudin-4 Receptor Overexpression: Novel Targets for a Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin. (1st October 2006)

Authors:
Santin, A. D.; Bandiera, E.; Comper, F.; Bellone, M.; Marizzoni, S.; Zanolini, A.; Palmieri, M.; Siegel, E. R.; Mckinney, J.; Thomas, M.; Hennings, L.; Roman, J. J.; Burnett, A.; Cannon, M. J.; Pecorelli, S.
Journal:
International journal of gynecological cancer
Issue:
Volume 16(2006)Supplement 3
Page Start:
612
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. (September 2015)

Authors:
Garon, E.B.; Scagliotti, G.V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L.I.; Kalofonos, H.; Kim, J.H.; Gans, S.; Brustugun, O.T.; Orlov, S.V.; Ferry, D.; Melemed, A.; Carter, G.C.; Zimmermann, A.H.; Treat, J.A.; Alexandris, E.; Lee, P.; Socinski, M.A.; Perol, M.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S621
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗